ArticleBMC infectious diseases2022
Prevalence of vaginal HPV infection among adolescent and early adult girls in Jos, North-Central Nigeria.
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Distribution of high- and low-risk human papillomavirus genotypes and their prophylactic vaccination coverage among West African women: systematic review.Journal of the Egyptian National Cancer Institute · 2023Pooled it
- Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Advancing the elimination of cervical cancer across Africa.Nature communications · 2026Review
- Early implementation and contextual determinants of the human papillomavirus vaccine rollout and uptake in Nigeria: a mixed-methods study.Frontiers in public health · 2026Article
- Increased proportion of "other hrHPV" genotypes other than 16 and 18/45 among women attending ART clinic in Northern Uganda.Gynecologic oncology reports · 2025Article
- Participatory implementation science to enhance knowledge and build the capacity to increase the uptake and sustainability of HPV vaccination among girls in Nigeria.Journal of health, population, and nutrition · 2025Article
- High Concordance between Vaginal Samples and Cervical Samples of Human Papillomavirus in Women Living with HIV in Rwanda.BMC infectious diseases · 2025Article
- Periodontal Status and Herpesiviridae, Bacteria, and Fungi in Gingivitis and Periodontitis of Systemically Compromised Pediatric Subjects: A Systematic Review.Children (Basel, Switzerland) · 2025Review
- Intent to Receive Human Papillomavirus Vaccination among School-going Pre-teens and Adolescent Girls.International journal of MCH and AIDS · 2025Article
- HPV vaccine hesitancy among parents and caregivers of adolescents in Northern Nigeria.Vaccine: X · 2024Article
- Article
- Prevalence and genotype distribution of human papillomavirus infection among women in Jingzhou, China: a population-based study of 51,720 women.Virology journal · 2023Article
- Knowledge about HPV Infection and the HPV Vaccine among Parents in Southeastern Serbia.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeKnowledge of the prevalence of HPV infection among adolescent and early adult girls is essential to determining the best age for the introduction of HPV vaccine, monitoring vaccine efficacy, and giving insight into determinants of persistent high-risk HPV infection, a necessary cause of cervical cancer. Yet, there have been limited studies of HPV infection among adolescent and early adult girls in low-and-middle-income countries.
methodsIn this cross-sectional study, we randomly selected 205 girls, aged 9-20 years, from 10 schools in central Nigeria. We obtained informed consent and assent, collected data, and trained participants to self-collect vaginal samples using swab stick. We genotyped HPV using SPF
resultsThe mean (SD) age of the girls was 14.9 (2.3) years. We found HPV in 13.2% of vaginal swabs. The earliest age at which anyHPV and hrHPV infections were detected was 10 and 12 years respectively. The prevalence of any HPV peaked at 16 and 17 years, hrHPV at 16 years, lrHPV at 17 and 18 years and multiple hrHPV 18 years of age. The prevalence of hrHPV infection was 1.5% among the 9-12 years age group, 2.9% among 13-16 years and 3.4% among 17-20 years old. The commonest hrHPV types detected were 52 (3.9%), 18 (1.5%) and 51 (2.4%). The most common lrHPV types was 6 (2.9%).
conclusionThe prevalence of HPV infection in these urbanized young girls in Nigeria is high and commences after 9 years of age. HPV vaccination in this population should start at 9 years of age or younger to prevent the establishment of persistent HPV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.